Menu Search
Equities

Henan Lingrui Pharmaceutical Co Ltd

600285:SHH

Henan Lingrui Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)18.77
  • Today's Change-3.83 / -16.95%
  • Shares traded16.40m
  • 1 Year change+17.09%
  • Beta0.8965
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 19-Oct-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy0
Outperform4
Hold0
Sell0
Strong Sell0

Share price forecast in CNY

The 2 analysts offering 12 month price targets for Henan Lingrui Pharmaceutical Co., Ltd. have a median target of 30.05, with a high estimate of 30.50 and a low estimate of 29.60. The median estimate represents a 31.39% increase from the last price of 22.87.
High33.4%30.50
Med31.4%30.05
Low29.4%29.60

Dividends

In 2023, Henan Lingrui Pharmaceutical Co Ltd reported a dividend of 0.80 CNY, which represents a 33.33% increase over last year. The 3 analysts covering the company expect dividends of 0.90 CNY for the upcoming fiscal year, an increase of 11.88%.
Div growth (TTM)33.33%
More ▼

Earnings history & estimates in CNY

Henan Lingrui Pharmaceutical Co., Ltd. reported annual 2023 earnings of 1.00 per share on Apr 25, 2024.
Average growth rate+28.92%
More ▼

Revenue history & estimates in CNY

Henan Lingrui Pharmaceutical Co., Ltd. had revenues for the full year 2023 of 3.31bn. This was 10.31% above the prior year's results.
Average growth rate+16.40%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.